KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to -$856.8 million.

  • Biogen's Net Cash Flow fell 21420.95% to -$856.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $531.6 million, marking a year-over-year decrease of 6183.23%. This contributed to the annual value of $531.6 million for FY2025, which is 6183.23% down from last year.
  • As of Q4 2025, Biogen's Net Cash Flow stood at -$856.8 million, which was down 21420.95% from $1.1 billion recorded in Q3 2025.
  • In the past 5 years, Biogen's Net Cash Flow registered a high of $1.1 billion during Q3 2025, and its lowest value of -$1.3 billion during Q4 2023.
  • For the 5-year period, Biogen's Net Cash Flow averaged around $86.2 million, with its median value being -$16.6 million (2021).
  • The largest annual percentage gain for Biogen's Net Cash Flow in the last 5 years was 71859.27% (2022), contrasted with its biggest fall of 52292.44% (2022).
  • Over the past 5 years, Biogen's Net Cash Flow (Quarter) stood at $735.4 million in 2021, then plummeted by 143.99% to -$323.5 million in 2022, then tumbled by 297.5% to -$1.3 billion in 2023, then soared by 158.34% to $750.2 million in 2024, then crashed by 214.21% to -$856.8 million in 2025.
  • Its Net Cash Flow was -$856.8 million in Q4 2025, compared to $1.1 billion in Q3 2025 and $92.2 million in Q2 2025.